Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Can GenAI solve the pension IHT problem
There’s a big change coming to defined contribution pensions in April 2027, when the current inheritance tax exemptions fall away. The changes potenti
Models underestimating climate signal from winter rainfall
Discover four ways U.K. winter storms are changing, what’s driving the shift, and how re/insurers can respond. The winter of 2023/24 was one of the we
Why HR leaders must rethink workforce design in the AI age
As artificial intelligence becomes embedded across UK organisations, its impact on workforce structures is already being felt. Research from Barnett W

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.